AVALO THERAPEUTICS, INC. Increase (Decrease) in Other Receivables
AVALO THERAPEUTICS, INC. (AVTX) reported Increase (Decrease) in Other Receivables of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-03-23
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2024-12-31 was -$387.00K.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2024-09-30 was $965.00K, a 37.01% decline year-over-year.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2024-06-30 was -$2.00K.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2024-03-31 was -$101.00K.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2024 was $475.00K.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2023 was -$1.78M.
- AVALO THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2022 was -$1.82M, a 218.88% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 3 month as first filed | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 6 month as first filed | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 9 month as first filed | Increase (Decrease) in Other Receivables 12 month | Increase (Decrease) in Other Receivables 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 | |||||||
| 2024-12-31 | -$387.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $578.00K derived: sum of 2 quarters · filed 2026-03-23 | $576.00K derived: sum of 3 quarters · filed 2026-03-23 | $475.00K 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $965.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $963.00K derived: sum of 2 quarters · filed 2024-11-07 | $862.00K 10-Q · filed 2024-11-07 | -$540.00K derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2024-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-12 | -$103.00K 10-Q · filed 2024-08-12 | -$1.50M derived: sum of 3 quarters · filed 2025-03-20 | $27.00K derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2024-03-31 | -$101.00K 10-Q/A · filed 2024-07-11 | -$1.50M derived: sum of 2 quarters · filed 2025-03-20 | $29.00K derived: sum of 3 quarters · filed 2025-03-20 | -$822.00K derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2023-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $130.00K derived: sum of 2 quarters · filed 2025-03-20 | -$721.00K derived: sum of 3 quarters · filed 2025-03-20 | -$1.78M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $681.00K derived: sum of 2 quarters · filed 2024-11-07 | -$381.00K 10-Q · filed 2024-11-07 | $224.00K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$851.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-12 | -$1.91M 10-Q · filed 2024-08-12 | -$1.31M derived: sum of 3 quarters · filed 2024-08-12 | -$1.30M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | -$1.06M 10-Q/A · filed 2024-07-11 | -$457.00K derived: sum of 2 quarters · filed 2024-07-11 | -$449.00K derived: sum of 3 quarters · filed 2024-07-11 | -$588.00K derived: sum of 4 quarters · filed 2024-07-11 | ||||
| 2022-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $613.00K derived: sum of 2 quarters · filed 2024-03-29 | $474.00K derived: sum of 3 quarters · filed 2024-03-29 | -$1.82M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$131.00K derived: sum of 2 quarters · filed 2023-11-09 | -$2.42M 10-Q · filed 2023-11-09 | -$1.16M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.43M 10-Q · filed 2023-08-03 | -$1.17M derived: sum of 3 quarters · filed 2023-08-03 | $308.00K derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | -$2.29M 10-Q · filed 2023-05-04 | -$1.03M derived: sum of 2 quarters · filed 2023-05-04 | $447.00K derived: sum of 3 quarters · filed 2023-05-04 | -$611.00K derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $2.74M derived: sum of 2 quarters · filed 2023-03-29 | $1.68M derived: sum of 3 quarters · filed 2023-03-29 | $1.53M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $421.00K derived: sum of 2 quarters · filed 2022-11-07 | $269.00K 10-Q · filed 2022-11-07 | -$1.81M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.21M 10-Q · filed 2022-08-04 | -$3.29M derived: sum of 3 quarters · filed 2022-08-04 | -$955.00K derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$152.00K 10-Q · filed 2022-05-05 | -$2.23M derived: sum of 2 quarters · filed 2022-05-05 | $103.00K derived: sum of 3 quarters · filed 2022-05-05 | -$8.00K derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | -$2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $255.00K derived: sum of 2 quarters · filed 2022-03-02 | $144.00K derived: sum of 3 quarters · filed 2022-03-02 | $2.11M 10-K · filed 2022-03-02 | $2.11M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.22M derived: sum of 2 quarters · filed 2021-11-09 | $4.18M 10-Q · filed 2021-11-09 | $4.18M 10-Q · filed 2020-11-09 | $4.32M derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2020-06-30 | -$111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $1.85M 10-Q · filed 2021-08-02 | $1.85M 10-Q · filed 2020-08-06 | $1.99M derived: sum of 3 quarters · filed 2021-08-02 | $2.06M derived: sum of 4 quarters · filed 2021-08-02 | |||
| 2020-03-31 | $1.96M 10-Q · filed 2021-05-13 | $1.96M 10-Q · filed 2020-05-07 | $2.10M derived: sum of 2 quarters · filed 2021-05-13 | $2.17M derived: sum of 3 quarters · filed 2021-05-13 | -$3.22M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $140.56K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $205.75K derived: sum of 2 quarters · filed 2021-03-08 | -$5.18M derived: sum of 3 quarters · filed 2021-03-08 | -$5.12M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $65.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$5.32M derived: sum of 2 quarters · filed 2020-11-09 | -$5.26M 10-Q · filed 2020-11-09 | -$6.06M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | -$5.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$5.33M 10-Q · filed 2020-08-06 | -$6.12M derived: sum of 3 quarters · filed 2020-08-06 | -$2.71M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $62.01K 10-Q · filed 2020-05-07 | -$733.46K derived: sum of 2 quarters · filed 2020-05-07 | $2.68M derived: sum of 3 quarters · filed 2020-05-07 | $2.71M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$795.47K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $2.62M derived: sum of 2 quarters · filed 2020-03-11 | $2.65M derived: sum of 3 quarters · filed 2020-03-11 | $2.28M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $3.44M derived: sum of 2 quarters · filed 2019-11-14 | $3.07M 10-Q · filed 2019-11-14 | $3.50M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $32.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$339.22K 10-Q · filed 2019-08-08 | $88.02K derived: sum of 3 quarters · filed 2019-08-08 | $88.02K derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | -$371.66K 10-Q · filed 2019-05-09 | $55.58K derived: sum of 2 quarters · filed 2019-05-09 | $55.58K derived: sum of 3 quarters · filed 2019-05-09 | $55.58K derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $427.24K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $427.24K derived: sum of 2 quarters · filed 2019-03-18 | $427.24K derived: sum of 3 quarters · filed 2019-03-18 | $427.24K 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | $0.00 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |